Source: Annual Congress 2002 - Drug resistance
Disease area: Respiratory infections

Abstract

The aim of the study was to evaluate the results of individual therapy regimens in patients /pts/ with multidrug resistant tuberculosis /MDRTB/.
The bacteriological, radiological and clinical findings in 17 pts were evaluated. All pts used individual combination of 4-5 drugs according to the results of drug susceptibility tests. Only 2 pts /12%/ had resistance for HR,6 pts /35%/ were resistant for 3 and 9 pts /53%/ even for 4 drugs of basic antituberculous drugs /AT/. The average duration of treatment of MDRTB was 11,6 months till the end of 2001.
Sputum conversion was achieved in 7 pts /41%/. Radiological findings with decrease of infiltration were found in 4 pts, without changes remained in 12 and worsening was in 1 case. Clinical features with remove of typical complaints were improved in 11 pts /65%/ while in 6 pts remained in the same status and 3 of them died due to pulmonary embolism.
We conclude the long-term treatment of MDRTB with combination of sensitive drugs in DOTS method is necessary. The outcomes are the best in clinical features /65%/ while bacteriological findings are changed only in 41%. Radiological response is very slow in one year period and reduce of infiltration is found in 23% of pts.

Rating:

Share or cite this content

Citations should be made in the following way:
V. Bartu, E. Kopecka, M. Vasakova (). Unit of multidrug resistant tuberculosis - effect of treatment. Eur Respir J 2002; 20: Suppl. 38, 3836

Member's Comments

No comment yet.

Related content which might interest you: Treatment of multidrug resistant pulmonary tuberculosis (MDR-TB) with different pattern of resistance Source: Eur Respir J 2004; 24: Suppl. 48, 723s Year: 2004 Second and third line anti-tuberculosis drug's side effects during the treatment of patients with multidrug resistant tuberculosis (MDR TB) Source: Eur Respir J 2003; 22: Suppl. 45, 555s Year: 2003 Multidrug resistant tuberculosis (MDR – TB) treatment outcomes in Iran Source: Eur Respir J 2004; 24: Suppl. 48, 657s Year: 2004 Treatment possibilities of multi-drug resistant (MDR) tuberculosis Source: Eur Respir J 2003; 22: Suppl. 45, 525s Year: 2003 Treatment results of multidrug resistant pulmonary tuberculosis (MDR-TB) Source: Eur Respir J 2005; 26: Suppl. 49, 199s Year: 2005 Outcomes of patients with multidrug resistant tuberculosis Source: Eur Respir J 2005; 26: Suppl. 49, 652s Year: 2005 Treatment outcome of multi-drug resistant tuberculosis Source: Annual Congress 2004 - Problems of resistance and HIV coinfection in tuberculosis Year: 2004 Short course of chemotherapy of multidrug resistant tuberculosis (MDR TB) Source: Eur Respir J 2004; 24: Suppl. 48, 722s Year: 2004 Effectiveness of the WHO regimen for treatment of multidrug resistant tuberculosis (MDR-TB) Source: Annual Congress 2013 –Drug-resistant tuberculosis: new clinical and public health insights Year: 2013 The surgery of multidrug resistant tuberculosis Source: Eur Respir J 2003; 22: Suppl. 45, 556s Year: 2003 Treatment outcome of multidrug resistant tuberculosis with second line drugs Source: Eur Respir J 2001; 18: Suppl. 33, 314s Year: 2001 Surgical treatment of multidrug resistant pulmonary tuberculosis (MDR-TB) Source: Annual Congress 2009 - Treatment of tuberculosis at times of emerging drug resistance Year: 2009 Side effect profile of 2nd line drugs in multi drug resistant (MDR) and extensively drug resistant (XDR) tuberculosis Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes Year: 2015 Evaluation of characteristics and treatment results of patients treated as multidrug resistant tuberculosis Source: Annual Congress 2012 - MDR- and XDR-TB: clinical and public health experiences Year: 2012 Our experience in multi drug resistant tuberculosis (MDR TB) treatment Source: Eur Respir J 2005; 26: Suppl. 49, 652s Year: 2005 Amikacin treatment for multidrug resistant tuberculosis: how much monitoring is required? Source: Eur Respir J 2013; 42: 1148-1150 Year: 2013 Multidrug resistance after inappropriate tuberculosis treatment: a meta-analysis Source: Eur Respir J 2012; 39: 1511-1519 Year: 2012 Effectiveness and safety of imipenem/clavulanate- versus meropenem/clavulanate-containing regimens in the treatment of multidrug resistant tuberculosis Source: International Congress 2016 – Rifampicin resistance, MDRTB, and new drug treatments Year: 2016 Treatment outcome of multi-drug resistant tuberculosis in Varanasi, India Source: Eur Respir J 2002; 20: Suppl. 38, 615s Year: 2002 Surgical treatment of destructive pulmonary tuberculosis (TB) with multi-drug resistance (MDR) Source: Eur Respir J 2004; 24: Suppl. 48, 723s Year: 2004